- Home
- OIA vs ITOS Comparison
OIA vs ITOS Comparison
Compare OIA & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OIA
- ITOS
- Stock Information
- Founded
- OIA 1988
- ITOS 2011
- Country
- OIA United States
- ITOS United States
- Employees
- OIA N/A
- ITOS N/A
- Industry
- OIA Finance Companies
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OIA Finance
- ITOS Health Care
- Exchange
- OIA Nasdaq
- ITOS Nasdaq
- Market Cap
- OIA 287.4M
- ITOS 270.7M
- IPO Year
- OIA N/A
- ITOS 2020
- Fundamental
- Price
- OIA $6.04
- ITOS $6.50
- Analyst Decision
- OIA
- ITOS Strong Buy
- Analyst Count
- OIA 0
- ITOS 3
- Target Price
- OIA N/A
- ITOS $26.00
- AVG Volume (30 Days)
- OIA 97.9K
- ITOS 382.6K
- Earning Date
- OIA 01-01-0001
- ITOS 03-05-2025
- Dividend Yield
- OIA 4.88%
- ITOS N/A
- EPS Growth
- OIA N/A
- ITOS N/A
- EPS
- OIA N/A
- ITOS N/A
- Revenue
- OIA N/A
- ITOS $35,000,000.00
- Revenue This Year
- OIA N/A
- ITOS N/A
- Revenue Next Year
- OIA N/A
- ITOS $121.70
- P/E Ratio
- OIA N/A
- ITOS N/A
- Revenue Growth
- OIA N/A
- ITOS 177.89
- 52 Week Low
- OIA $4.93
- ITOS $6.32
- 52 Week High
- OIA $6.72
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- OIA 48.69
- ITOS 34.92
- Support Level
- OIA $5.91
- ITOS $6.72
- Resistance Level
- OIA $6.15
- ITOS $7.05
- Average True Range (ATR)
- OIA 0.07
- ITOS 0.33
- MACD
- OIA 0.01
- ITOS -0.05
- Stochastic Oscillator
- OIA 57.69
- ITOS 13.53
About OIA Invesco Municipal Income Opportunities Trust
Invesco Muni Income Opps Trust operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income which is exempt from federal income tax.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.